Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MARGENZA vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Margetuximab is an Fc-engineered monoclonal antibody that targets the extracellular domain of human epidermal growth factor receptor 2 (HER2). It binds to HER2 on tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) via enhanced affinity for activating Fcγ receptors (FcγRIIIa) and reduced affinity for inhibitory FcγRIIb, thereby augmenting immune effector cell activation.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
FDA-approved: In combination with chemotherapy (capecitabine or gemcitabine plus cisplatin) for the treatment of adults with metastatic or locally advanced unresectable HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received two or more prior anti-HER2 regimens.,Off-label: Not specified in FDA labeling; potential off-label uses may include other HER2-positive malignancies, but none are established.
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
15 mg/kg intravenously over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Terminal half-life approximately 17-23 days (mean ~20 days) following intravenous administration, supporting a 3-week dosing interval for sustained receptor occupancy.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Margetuximab is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic enzymes or pathways are involved.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Primarily cleared via proteolytic degradation; renal excretion of intact drug is negligible (<1%). No significant biliary or fecal elimination reported.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
~99% bound to plasma proteins, primarily to albumin and immunoglobulin G (as a monoclonal antibody).
82–88% bound to plasma proteins (primarily albumin).
Volume of distribution approximately 3.0-4.0 L (0.04-0.06 L/kg). Low Vd indicates limited extravascular distribution, consistent with large antibody molecule primarily confined to plasma and interstitial space.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Bioavailability is 100% by intravenous route as it is administered as an IV infusion; not available for oral or other routes.
Oral: 65–80% (median 73%)
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
No dose adjustment recommended for mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN, or total bilirubin >1-1.5× ULN with any AST). Not studied in moderate (total bilirubin >1.5-3× ULN with any AST) or severe (total bilirubin >3× ULN with any AST) hepatic impairment.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Safety and effectiveness in pediatric patients have not been established.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
No specific dose adjustment recommended. Of the 292 patients treated with MARGENZA in the SOPHIA trial, 45% were aged 65 years or older, 11% were 75 or older. No overall differences in efficacy or safety observed between elderly and younger patients.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
No black box warning exists for MARGENZA.
None
Cardiotoxicity: Left ventricular ejection fraction (LVEF) decline; assess LVEF prior to and during treatment. Discontinue for symptomatic heart failure or persistent decline.,Infusion-related reactions: Monitor during infusion; reduce rate or discontinue for severe reactions.,Embryo-fetal toxicity: Can cause fetal harm; advise females of reproductive potential of the risk and use effective contraception.,Pulmonary toxicity: Interstitial lung disease and pneumonitis; monitor for signs/symptoms and permanently discontinue if confirmed.,Neutropenia and febrile neutropenia: May occur; monitor blood counts.,Hypokalemia and hypomagnesemia: Monitor electrolytes and replace as needed.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
None known.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
No specific food interactions are known. No dietary restrictions required during treatment.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
MARGENZA (margetuximab-cmkb) is an Ig G1 monoclonal antibody. Based on its mechanism of action (HER2/neu receptor blockade) and findings from animal studies with other HER2-targeted agents, it is expected to cause fetal harm or death when administered to a pregnant woman. Human Ig G molecules cross the placenta, with increasing transfer as pregnancy progresses, reaching peak levels during the third trimester. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may have lower risk, but second and third trimester exposure is associated with oligohydramnios, fetal renal dysfunction, and fetal loss.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
There are no data on the presence of margetuximab in human milk, its effects on the breastfed infant, or its effects on milk production. Maternal Ig G is present in human milk, but the amount of margetuximab transferred is expected to be low due to its large molecular size. However, because of the potential for serious adverse reactions in nursing infants, women should discontinue breastfeeding during treatment and for at least 4 months after the last dose. M/P ratio is not available.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
No dosage adjustment is recommended for MARGENZA based on pregnancy-induced pharmacokinetic changes; however, the drug should be avoided during pregnancy due to fetal harm. No specific pharmacokinetic studies have been conducted in pregnant women to warrant dose adjustments.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
MARGENZA (margetuximab-cmkb) is an anti-HER2 monoclonal antibody indicated in combination with chemotherapy for metastatic HER2-positive breast cancer after two or more prior anti-HER2 regimens. Premedicate with acetaminophen, diphenhydramine, and corticosteroids to mitigate infusion-related reactions. Monitor for left ventricular ejection fraction (LVEF) decline; assess cardiac function at baseline and every 3 months during treatment. Use with caution in patients with prior anthracycline exposure or pre-existing cardiac dysfunction.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
MARGENZA is given as an intravenous infusion every 3 weeks; each infusion takes about 90 minutes initially, then 30 minutes if well tolerated.,You may experience infusion-related reactions such as fever, chills, or nausea; you will receive premedication to reduce these.,This drug can cause heart problems; your doctor will monitor your heart function with echocardiograms regularly.,MARGENZA can cause fetal harm if used during pregnancy; use effective contraception during treatment and for 4 months after the last dose.,Do not breastfeed during treatment and for 4 months after the last dose.,Common side effects include fatigue, nausea, diarrhea, and anemia.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MARGENZA vs AGRYLIN, answered by our medical review team.
MARGENZA is a Antineoplastic Agent that works by Margetuximab is an Fc-engineered monoclonal antibody that targets the extracellular domain of human epidermal growth factor receptor 2 (HER2). It binds to HER2 on tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) via enhanced affinity for activating Fcγ receptors (FcγRIIIa) and reduced affinity for inhibitory FcγRIIb, thereby augmenting immune effector cell activation.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MARGENZA and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MARGENZA is: 15 mg/kg intravenously over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MARGENZA and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MARGENZA is classified as Category C. MARGENZA (margetuximab-cmkb) is an IgG1 monoclonal antibody. Based on its mechanism of action (HER2/neu receptor blockade) and findings from animal studies with other HER2-targeted. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.